tetano
Editor, Senior Moderator
Eur J Cancer
. 2020 Sep 2;139:43-50.
doi: 10.1016/j.ejca.2020.08.011. Online ahead of print.
Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies
Kamal S Saini[SUP] 1 [/SUP], Marco Tagliamento[SUP] 2 [/SUP], Matteo Lambertini[SUP] 2 [/SUP], Richard McNally[SUP] 3 [/SUP], Marco Romano[SUP] 3 [/SUP], Manuela Leone[SUP] 3 [/SUP], Giuseppe Curigliano[SUP] 4 [/SUP], Evandro de Azambuja[SUP] 5 [/SUP]
Affiliations
Abstract
Background: Patients with coronavirus disease 2019 (COVID-19) who have underlying malignancy have a higher mortality rate compared with those without cancer, although the magnitude of such excess risk is not clearly defined. We performed a systematic review and pooled analysis to provide precise estimates of the mortality rate among patients with both cancer and COVID-19.
Methods: A systematic literature search involving peer-reviewed publications, preprints and conference proceedings up to July 16, 2020, was performed. The primary end-point was the case fatality rate (CFR), defined as the rate of death among patients with cancer and COVID-19. The CFR was assessed with a random effects model, which was used to derive a pooled CFR and its 95% confidence interval (CI).
Results: Fifty-two studies, involving a total of 18,650 patients with both COVID-19 and cancer, were selected for the pooled analysis. A total of 4243 deaths were recorded in this population. The probability of death was 25.6% (95% CI: 22.0%-29.5%; I[SUP]2[/SUP] = 48.9%) in this patient population.
Conclusions: Patients with cancer who develop COVID-19 have high probability of mortality. Appropriate and aggressive preventive measures must be taken to reduce the risk of COVID-19 in patients with cancer and to optimally manage those who do contract the infection.
Keywords: CFR; COVID-19; Cancer; Death rate; Malignancy; Mortality; Pandemic; SARS-CoV-2
. 2020 Sep 2;139:43-50.
doi: 10.1016/j.ejca.2020.08.011. Online ahead of print.
Mortality in patients with cancer and coronavirus disease 2019: A systematic review and pooled analysis of 52 studies
Kamal S Saini[SUP] 1 [/SUP], Marco Tagliamento[SUP] 2 [/SUP], Matteo Lambertini[SUP] 2 [/SUP], Richard McNally[SUP] 3 [/SUP], Marco Romano[SUP] 3 [/SUP], Manuela Leone[SUP] 3 [/SUP], Giuseppe Curigliano[SUP] 4 [/SUP], Evandro de Azambuja[SUP] 5 [/SUP]
Affiliations
- PMID: 32971510
- DOI: 10.1016/j.ejca.2020.08.011
Abstract
Background: Patients with coronavirus disease 2019 (COVID-19) who have underlying malignancy have a higher mortality rate compared with those without cancer, although the magnitude of such excess risk is not clearly defined. We performed a systematic review and pooled analysis to provide precise estimates of the mortality rate among patients with both cancer and COVID-19.
Methods: A systematic literature search involving peer-reviewed publications, preprints and conference proceedings up to July 16, 2020, was performed. The primary end-point was the case fatality rate (CFR), defined as the rate of death among patients with cancer and COVID-19. The CFR was assessed with a random effects model, which was used to derive a pooled CFR and its 95% confidence interval (CI).
Results: Fifty-two studies, involving a total of 18,650 patients with both COVID-19 and cancer, were selected for the pooled analysis. A total of 4243 deaths were recorded in this population. The probability of death was 25.6% (95% CI: 22.0%-29.5%; I[SUP]2[/SUP] = 48.9%) in this patient population.
Conclusions: Patients with cancer who develop COVID-19 have high probability of mortality. Appropriate and aggressive preventive measures must be taken to reduce the risk of COVID-19 in patients with cancer and to optimally manage those who do contract the infection.
Keywords: CFR; COVID-19; Cancer; Death rate; Malignancy; Mortality; Pandemic; SARS-CoV-2